Malignant Paraganglioma: Clinical Trials

2 trials for Malignant Paraganglioma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow Malignant Paraganglioma: new trials by email Literature Review of Malignant Paraganglioma trials Research Report on Malignant Paraganglioma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
anlotinib hydrochloride - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Phase 2CompletedPeking Union Medical College Hospital272021-04-302024-06-12
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Phase 2CompletedMayo Clinic32017-05-312024-02-20

Narrower conditions

Paraganglioma, Extra-Adrenal (2)  ·  Pheochromocytoma (2)  ·  Neoplasm Metastasis (1)  ·  Paraganglioma (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Neuroectodermal Tumors (2)  ·  Neuroendocrine Tumors (2)  ·  Neoplastic Processes (1)  ·  Paraganglioma (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

anlotinib (1)  ·  lenvatinib (1)

Sponsors

Mayo Clinic (1)  ·  Peking Union Medical College Hospital (1)

Countries

China (1)  ·  United States (1)

Top investigators

Anli Tong (1)  ·  Ashish Chintakuntlawar (1)

NIH funding

P30CA015083 (1)